Radiotherapy as a New Player in Immuno-Oncology

Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shang-Jui, Haffty, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315809/
https://www.ncbi.nlm.nih.gov/pubmed/30558196
http://dx.doi.org/10.3390/cancers10120515
_version_ 1783384382639177728
author Wang, Shang-Jui
Haffty, Bruce
author_facet Wang, Shang-Jui
Haffty, Bruce
author_sort Wang, Shang-Jui
collection PubMed
description Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted.
format Online
Article
Text
id pubmed-6315809
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63158092019-01-09 Radiotherapy as a New Player in Immuno-Oncology Wang, Shang-Jui Haffty, Bruce Cancers (Basel) Review Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted. MDPI 2018-12-14 /pmc/articles/PMC6315809/ /pubmed/30558196 http://dx.doi.org/10.3390/cancers10120515 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Shang-Jui
Haffty, Bruce
Radiotherapy as a New Player in Immuno-Oncology
title Radiotherapy as a New Player in Immuno-Oncology
title_full Radiotherapy as a New Player in Immuno-Oncology
title_fullStr Radiotherapy as a New Player in Immuno-Oncology
title_full_unstemmed Radiotherapy as a New Player in Immuno-Oncology
title_short Radiotherapy as a New Player in Immuno-Oncology
title_sort radiotherapy as a new player in immuno-oncology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315809/
https://www.ncbi.nlm.nih.gov/pubmed/30558196
http://dx.doi.org/10.3390/cancers10120515
work_keys_str_mv AT wangshangjui radiotherapyasanewplayerinimmunooncology
AT hafftybruce radiotherapyasanewplayerinimmunooncology